期刊文献+

美沙拉嗪联合川芎嗪治疗溃疡性结肠炎的临床疗效 被引量:4

The clinical effect of mesalazine combined with ligustrazine in treating ulcerative colitis
下载PDF
导出
摘要 目的:观察美沙拉嗪联合川芎嗪治疗溃疡性结肠炎的临床疗效。方法:将60例溃疡性结肠炎患者随机分为对照组及观察组,每组30例。在溃疡性结肠炎常规治疗的基础上,对照组给予美沙拉嗪1.0g,3次/d;观察组同时给予盐酸川芎嗪葡萄糖注射液100ml,1次/d静脉滴注及美沙拉嗪1.0g,3次/d;两组疗程均为8周。8周后评价疗效。结果:观察组总有效率为90%,显效率为70%,均高于对照组的80%及50%,差异有统计学意义(P<0.05)。结论:美沙拉嗪和川芎嗪联合治疗溃疡性结肠炎具有更好的临床疗效,能较好地改善患者的临床症状及体征。 0bjective: To evaluate the effect of mesalazine combined with ligustrazine in treating ulcerative colitis patients. Methods: Sixty patients with ulcerative colitis were randomly divided into observation group and control group, thirty patients in each group. On the foundation treatment of ulcerative colitis, the control group received mesalazine 1.0 g, three times a day. And at the same time the observation group received Ligustrazine glucose 100 ml one time each day by injection. All the patients received a course of 8 weeks. Then the effect of the treatment was evaluated. Results: The total effective rate and significant efficiency rate of observation group were 90% and 70%, compared with control group's 80% and 50%, the diference was statistically significant (P0.05). Conclusion: The combination therapy in treatment of ulcerative colitis is better. It can improve the patient's clinical symptoms and signs better.
出处 《中国当代医药》 2011年第29期86-87,共2页 China Modern Medicine
关键词 溃疡性结肠炎 美沙拉嗪 川芎嗪 疗效观察 Ulcerative colitis Mesalazine Ligustrazine Effect observation
  • 相关文献

参考文献8

二级参考文献27

  • 1王立春,马鑫.慢性溃疡性结肠炎治疗进展[J].中国医疗前沿(学术版),2008,3(1):37-39. 被引量:23
  • 2Branislav R Filipovi,Branka F Filipovi,Mirko Kerkez,Nikola Milini,Tomislav Ran■elovi.Depression and anxiety levels in therapy-nave patients with inflammatory bowel disease and cancer of the colon[J].World Journal of Gastroenterology,2007,13(3):438-443. 被引量:11
  • 3潘国宗 刘彤华 见:潘国宗 曹世植9. 主编.溃疡性结肠炎[A].见:潘国宗,曹世植9.,主编.现代胃肠病学.第Ⅰ版[C].北京:科学出版社,1994.1246-1247.
  • 4潘国宗 刘彤华.Crohn病[A].见:潘国宗 曹世植 主编.现代胃肠病学[C].北京:科学出版社,1994.1154.
  • 5Ouyang Q,Tandon R,Goh KL,et al.The emergence of inflammatory bowel disease in the Asian Pacific region.Curr Opin Gastroenterol,2005,21 (4):408-413.
  • 6Satsangi J,Silverberg MS,Vermeire S,et al.The Montreal classification of inflammatory bowel disease:controversies,consensus,and implications.Gut,2006,55(6):749-753.
  • 7Kornbluth A,Sachar DB; Practice Parameters Committee of the American College of Gastroenterology.Ulcerative colitis practice guidelines in adults (update):American College of Gastroenterology,Practice Parameters Committee.Am J Gastroenterol,2004,99 (7):1371-1385.
  • 8Hanauer SB,Sandborn W; Practice Parameters Committee of the American College of Gastroenterology.Management of Crohn's disease in adults.Am J Gastroenterol,2001,96 (3):635-643.
  • 9Stange EF,Travis SP,Vermeire S,et al.European Crohn's and Colitis Organisation.European evidence based consensus on the diagnosis and management of Crohn's disease:definitions and diagnosis.Gut,2006,55Suppl 1:i1-i15.
  • 10Carter MJ,Lobo AJ,Travis SP; IBD Section,British Society of Gastroenterology.Guidelines for the management of inflammatory bowel disease in adults.Gut,2004,53 Suppl 5:V1-V16.

共引文献2053

同被引文献79

引证文献4

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部